If confirmed in a longitudinal study, neurodegeneration of the afferent visual system measured by OCT may be used as a sensitive and easily accessible marker of global neurodegeneration in SCA‐ATXN1 and—in the light of approaching therapeutic candidates—even serve as outcome candidate for clinical trials.4, 36. The gene discussed is ATXN1; the disease is autosomal dominant cerebellar ataxia.